GIM
TEVA icon

Greylin Investment Management’s Teva Pharmaceuticals TEVA Stock Holding History

Greylin Investment Management’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-112,515
Closed -$1.76M – 77
2019
Q1 		$1.76M Sell
112,515
-99,940
-47% -$1.76M 0.4% 36
2018
Q4 		$3.28M Sell
212,455
-24,440
-10% -$501K 0.79% 22
2018
Q3 		$5.1M Sell
236,895
-5,110
-2% -$119K 1.1% 20
2018
Q2 		$5.89M Sell
242,005
-5,150
-2% -$105K 1.27% 19
2018
Q1 		$4.22M Sell
247,155
-3,390
-1% -$66.2K 0.92% 21
2017
Q4 		$4.75M Buy
250,545
+20,680
+9% +$311K 1.03% 19
2017
Q3 		$4.05M Sell
229,865
-64,630
-22% -$1.45M 0.93% 20
2017
Q2 		$9.78M Buy
294,495
+79,300
+37% +$2.45M 2.26% 11
2017
Q1 		$6.91M Buy
215,195
+122,340
+132% +$4.18M 1.6% 12
2016
Q4 		$3.37M Buy
+92,855
New +$3.71M 0.81% 18
2016
Q1 		– Sell
-4,365
Closed -$287K – 77
2015
Q4 		$287K Sell
4,365
-500
-10% -$30.9K 0.08% 57
2015
Q3 		$275K Sell
4,865
-1,999
-29% -$130K 0.08% 45
2015
Q2 		$406K Sell
6,864
-1,200
-15% -$74K 0.1% 43
2015
Q1 		$464K Sell
8,064
-2,200
-21% -$128K 0.11% 43
2014
Q4 		$590K Sell
10,264
-450
-4% -$25.1K 0.14% 40
2014
Q3 		$576K Sell
10,714
-1,400
-12% -$74.2K 0.14% 43
2014
Q2 		$635K Sell
12,114
-1,400
-10% -$71.6K 0.15% 41
2014
Q1 		$714K Buy
13,514
+2,215
+20% +$102K 0.17% 42
2013
Q4 		$453K Buy
+11,299
New +$445K 0.11% 54

Other funds holding TEVA

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Berkshire Hathaway
Berkshire Hathaway Omaha, Nebraska $299B AUM 27.55% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACM
Abrams Capital Management Boston, Massachusetts $5.48B AUM 3.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Greylin Investment Management's TEVA Position: Q2 2019 in Review

Greylin Investment Management sold out of Teva Pharmaceuticals (TEVA) in Q2 2019, closing a stake of 112,515 shares — an estimated $1.76M sold.

Greylin Investment Management first reported a position in TEVA in Q4 2013 and held it in 19 quarters. The position peaked at $9.78M in Q2 2017. 452 funds tracked by Wall St. Rank hold TEVA as of Q2 2019.

  • Greylin Investment Management reported no remaining Teva Pharmaceuticals position as of Q2 2019 after selling out during the quarter.
  • Greylin Investment Management sold 112,515 Teva Pharmaceuticals shares in Q2 2019, an estimated $1.76M.
  • Greylin Investment Management first reported a position in Teva Pharmaceuticals in Q4 2013 and held it in 19 quarters.
  • Greylin Investment Management's Teva Pharmaceuticals position peaked at $9.78M in Q2 2017.
  • 452 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2019.

Based on Greylin Investment Management's 13F filing for Q2 2019, filed 15 Aug 2019.